Advances in Pharma Business Management and Research

Volume 1
1. Auflage 2020
ISBN: 978-3-030-35920-1
Verlag: Springer International Publishing

Buch, Englisch, 85 Seiten, Paperback, Format (B × H): 155 mm x 235 mm, Gewicht: 166 g

This open access book presents a unique collection of practical examples from the field of pharma business management and research. It covers a wide range of topics such as: 'Brexit and its Impact on pharmaceutical Law - Implications for Global Pharma Companies', 'Implementation of Measures and Sustainable Actions to Improve Employee's Engagement', 'Global Medical Clinical and Regulatory Affairs (GMCRA)', and 'A Quality Management System for R&D Project and Portfolio Management in a Pharmaceutical Company'.

The chapters are summaries of master’s theses by "high potential" Pharma MBA students from the Goethe Business School, Frankfurt/Main, Germany, with 8-10 years of work experience and are based on scientific know-how and real-world experience. The authors applied their interdisciplinary knowledge gained in 22 months of studies in the MBA program to selected practical themes drawn from their daily business.

Zielgruppe

Professional/practitioner

Autoren/Hrsg.

Schweizer, Lars

Jansen, Christian

Dingermann, Theodor

Russe, Otto Quintus

Fachgebiete

• Medizin | Veterinärmedizin Medizin | Public Health | Pharmazie | Zahnmedizin Medizinische Fachgebiete Pharmakologie, Toxikologie
• Rechtswissenschaften Öffentliches Recht Medizin- und Gesundheitsrecht
• Wirtschaftswissenschaften Betriebswirtschaft Bereichsspezifisches Management Betriebliches Gesundheitsmanagement
• Medizin | Veterinärmedizin Medizin | Public Health | Pharmazie | Zahnmedizin Pharmazie

Inhaltsverzeichnis

Chapter 1. Introduction: Trends and developments in the pharmaceutical and life sciences industry.- Chapter 2. Relevance of instruments for measurements of Quality of Life in the AMNOG Context.- Chapter 3. The quality management system for R&D project and portfolio management in a pharmaceutical company.- Chapter 4. Brexit and Its Impact on Pharmaceutical Law - Implications for global pharma companies.- Chapter 5. Implementation of Measurable and Sustainable Actions to Improve Employee’s Engagement and Business Performance - Global Medical Clinical & Regulatory Affairs (GMCRA) – A Role Model at Fresenius Kabi.- Chapter 6. Leadership Models and Work Behavior: An Empirical Analysis of Consequences of Authentic and Transformational Leadership.- Chapter 7. Alliance Management at Merck - Establishing an operational 100-day plan for alliance launches and management.

Über Autor(innen)

Dr. Lars Schweizer

Prof. Dr. Lars Schweizer has been a Professor of Strategic Management at Goethe University Frankfurt since December 2007. Currently, he is the Academic Director of the Master of Pharma Business Administration as well as the Master of Digital Transformation at Goethe Business School. He holds a doctoral degree and postdoctoral degree (habilitation) from the University of Bamberg. He has published papers in journals such as the Academy of Management Journal, the Strategic Management Journal, the Journal of Management, Industrial and Corporate Change, the Journal of General Management, Scandinavian Journal of Management, the Journal of Engineering and Technology Management, the International Journal of Biotechnology, Pharmaceutical Policy and Law, and the Journal of Business Research. His main research focuses are mergers & acquisitions, strategic management, leadership, and organizational behavior as well as the pharmaceutical and biotechnology industries.

Dr. Theodor Dingermann

Prof. Dr. rer. nat. Theodor Dingermann (1948) studied Pharmacy at the University of Erlangen-Nurnberg between 1973 and 1976. In 1980 he received his Ph.D. in Biochemistry. From 1980 to 1982 he worked as a postdoctoral fellow at Yale University, New Haven, USA with Prof. Dr. Dieter Söll. From 1990 to 2013 he was a Professor and Director of the Department of Pharmaceutical Biology at Goethe University Frankfurt/Main. Since 2013 he has been affiliated with the Goethe University as a Senior Professor. Prof. Dingermann received the Carl-Mannich-Medal Award from the German Pharmaceutical Society in 2010, and he was elected “Professor of the Year 2009” in Germany. He is editor-in-chief of the international scientific journal DIE PHARMAZIE, editor-in-chief of “Pharmakon”, the official journal of the German Pharmaceutical Society, and a member of the group of chiefeditors of the “Pharmazeutische Zeitung”.

Between 2005 and 2014, Prof. Dingermann was the Representative for Biotechnology for the State of Hessen. He is an elected member of the German Pharmaceutical Association’s Drug Commission (Arzneimittelkommission der Deutschen Apothekerschaft) and since 1992 has been Chairman of the working group "recombinant DNA products" of the German Pharmacopoeia committee at the BfArM. From 1996 to 2000 he was Vice President and from 2000 to 2004 President of the German Pharmaceutical Society (DPhG). From 1998 to 2000 he served as Vice President of Goethe University Frankfurt/Main.

At GBS, Prof. Dr. Dingermann is the Academic Director of the Master of Pharma Business Administration.

He is in great demand as a speaker at international events and author of numerous publications.

Dr. Otto Quintus Russe

Dr. Otto Quintus Russe has been the Managing Director of the House of Pharma & Healthcare at Goethe University Frankfurt since 2014. He studied Pharmacy at Goethe University Frankfurt from 2004 to 2008. After working in the pharmaceutical industry and public pharmacy, he completed his doctorate (2010-2014) on AMP-activated protein kinase as a target for the treatment of inflammatory nociception at the University Hospital Frankfurt.

Dr. Christian Jansen

Christian Jansen has been the Managing Director of Goethe Business School since 2013. Prior to joining GBS, Dr. Jansen worked as a consultant with McKinsey & Company for three years. He holds a diploma in Business Administration from Goethe University Frankfurt and a Master of Business Administration (MBA) degree from the University of Iowa, USA. In 2008, he completed his doctorate at the European Business School.